Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MabpharmHKSE:02181 40 Days Inventory is 648.59 as of Dec. 2025, which is 36% below its 10-year median of 1,012.93. GuruFocus rates HKSE:02181 with a GF Score™ of 40/100 and a GF Value™ of HK$1.99 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 637 Biotechnology companies, Mabpharm ranks worse than 86.66% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Mabpharm's Average Total Inventories for the
six
months ended in Dec. 2025 was HK$155.1 Mil. Mabpharm's Cost of Goods Sold for the
six
months ended in Dec. 2025 was HK$43.6 Mil.
Hence, Mabpharm's Days Inventory for the
six
months ended in Dec. 2025 was 648.59.
The historical rank and industry rank for Mabpharm's Days Inventory or its related term are showing as below:
HKSE:02181'
s Days Inventory Range Over the Past 10 Years
Min: 614.31 Med: 1012.93 Max: 3137.07
Current: 654.92
During the past 9 years, Mabpharm's highest Days Inventory was 3137.07. The lowest was 614.31. And the median was 1012.93.
HKSE:02181's Days Inventory is ranked worse than 86.66% of 637
companies
in the Biotechnology industry
Industry Median: 181.41
vs HKSE:02181: 654.92
Mabpharm's Days Inventory
declined
from Dec. 2024 (788.73) to Dec. 2025 (648.59).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Mabpharm's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.28.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Mabpharm's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.38.
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Mabpharm's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Mabpharm's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Mabpharm Days Inventory Related Terms
Mabpharm Days Inventory Historical Data
* Premium members only.
The historical data trend for Mabpharm's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02181 vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, Mabpharm's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mabpharm Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mabpharm's Days Inventory distribution charts can be found below:
* The bar in red indicates where Mabpharm's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mabpharm (HKSE:02181) has a Days Inventory of 648.59 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Mabpharm and its competitors. This is 36% below median its historical median of 1,012.93. Over the past decade, Mabpharm's Days Inventory has ranged from 614.31 to 3,137.07. According to the industry distribution chart, Mabpharm ranks #552 out of 637 companies in the Biotechnology industry, placing it in the top 86.7%.
Is Mabpharm's Days Inventory too high?
Mabpharm's current Days Inventory of 648.59 is 36% below median its 10-year median of 1,012.93. Over the past 10 years, this metric has ranged from a low of 614.31 to a high of 3,137.07. The Biotechnology industry median Days Inventory is 181.41. Mabpharm's value of 648.59 is 257.5% above this industry median. Based on the distribution chart, Mabpharm ranks #552 out of 637 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Mabpharm has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mabpharm's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mabpharm ranks #552 out of 637 companies for Days Inventory. This places Mabpharm in the lower half of its industry. The industry median Days Inventory is 181.41. Mabpharm's value of 648.59 is 257.5% above this benchmark. Historically, Mabpharm's own Days Inventory has ranged from 614.31 to 3,137.07 over the past decade. While the company's 10-year median is 1,012.93 vs. the industry median of 181.41, Mabpharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 181.41, based on 637 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mabpharm's current Days Inventory of 648.59 is 257.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Mabpharm and its competitors. For the Biotechnology industry, the median Days Inventory is 181.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mabpharm's current Days Inventory is 648.59, which is 36% below median its own 10-year median of 1,012.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabpharm stock overvalued right now?
Based on GuruFocus' analysis, Mabpharm (HKSE:02181) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.99, compared to a current price of HK$0.41 — trading 79.6% below its estimated fair value. The current Days Inventory is 648.59, which is 36% below median its 10-year median of 1,012.93 and 257.5% above the Biotechnology industry median of 181.41. Mabpharm's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Mabpharm (HKSE:02181), the current Days Inventory is 648.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mabpharm (HKSE:02181) Overvalued in 2026?
Based on GuruFocus' analysis, Mabpharm stock appears to be undervalued.
The current stock price of HK$0.41 is trading 79.6% below its estimated GF Value™ of HK$1.99.
GuruFocus considers Mabpharm to be Possible Value Trap.
Key valuation signals for HKSE:02181:
Days Inventory: 648.59 (36% below median its 10-year median of 1,012.93)
GF Value™: HK$1.99 vs. price of HK$0.41 (79.6% below fair value)
Industry Position: 257.5% above the Biotechnology median (#552 of 637)
No single metric tells the full story. See the HKSE:02181 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab). Company operates in Chinese Mainland and Others.
40GF Score
Get the complete analysis for HKSE:02181
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02181 has been successfully added to your 
